Articles
Page 4 of 20
-
Citation: BMC Pharmacology 2011 11(Suppl 1):P79
-
Dynamics of NO interacting with soluble guanylate cyclase from 1 ps to 0.1 s and induced structural transitions
Citation: BMC Pharmacology 2011 11(Suppl 1):P77 -
Activation of cGMP-dependent protein kinase Iα and cAMP-dependent protein kinase A isoforms by cyclic nucleotides
Citation: BMC Pharmacology 2011 11(Suppl 1):P76 -
The effector protein ExoY secreted by Pseudomonas aeruginosa is a nucleotidyl cyclase with preference for GTP
Citation: BMC Pharmacology 2011 11(Suppl 1):P74 -
Smooth muscle cell specific deletion of the PKGIα target RGS2 induces vascular dysfunction and hypertension
Citation: BMC Pharmacology 2011 11(Suppl 1):P72 -
cGMP-mediated antioxidant signaling: a role for the c-Abl tyrosine kinase
Citation: BMC Pharmacology 2011 11(Suppl 1):P70 -
Gemfibrozil as a potential heme-independent sGC activator
Citation: BMC Pharmacology 2011 11(Suppl 1):P68 -
Dynamic Vessel Analyzer (DVA) – a new method to detect endothelial dysfunction in chronic heart failure: correlation between DVA and asymmetric dimethyl arginine (ADMA)
Citation: BMC Pharmacology 2011 11(Suppl 1):P66 -
cGMP and PKGI are required for vascular BMP signaling
Citation: BMC Pharmacology 2011 11(Suppl 1):P65 -
Pharmacokinetic analysis of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in individuals with renal impairment compared to healthy controls
Citation: BMC Pharmacology 2011 11(Suppl 1):P61 -
C-Type natriuretic peptide: a potential urinary biomarker for renal remodeling and fibrosis during aging
Citation: BMC Pharmacology 2011 11(Suppl 1):P60 -
A novel natriuretic peptide
Citation: BMC Pharmacology 2011 11(Suppl 1):P50 -
cGMP and cAMP differentially regulate differentiation and function of brown adipocytes
Citation: BMC Pharmacology 2011 11(Suppl 1):P37 -
Role of NO/cGMP signalling in VEGF-mediated angiogenesis
Citation: BMC Pharmacology 2011 11(Suppl 1):P35 -
Cyclic CMP and cyclic UMP: new (old) second messengers
Citation: BMC Pharmacology 2011 11(Suppl 1):O34 -
Comparative efficacy of AHU-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension
Citation: BMC Pharmacology 2011 11(Suppl 1):P33 -
Protein kinase G type-I phosphorylates c-Src at serine-17 and promotes cell survival, proliferation and attachment in human mesothelioma and non-small cell lung cancer cells
Citation: BMC Pharmacology 2011 11(Suppl 1):O31 -
Biomarkers in two different animal models of pulmonary arterial hypertension (PAH) under treatment with a cGMP enhancing substance
Citation: BMC Pharmacology 2011 11(Suppl 1):P31 -
Rosiglitazone improves the natriuretic response to atrial natriuretic peptide in rats with experimental congestive heart failure: possible involvement of a post-guanylate cyclase mechanism
Citation: BMC Pharmacology 2011 11(Suppl 1):P29 -
cGMP modulates stem cells differentiation to neurons in brain in vivo pathological implications
Citation: BMC Pharmacology 2011 11(Suppl 1):O29 -
Regulation of vascular growth and tone by hydrogen sulfide
Citation: BMC Pharmacology 2011 11(Suppl 1):O27 -
Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
Citation: BMC Pharmacology 2011 11(Suppl 1):P26 -
cGMP/cGKI signaling in peripheral vascular smooth muscle does not involve TrpC3 or TrpC6 channels
Citation: BMC Pharmacology 2011 11(Suppl 1):O25 -
Src activation by cGMP/PKG II in osteoblasts: characterization of a mechano-sensitive signalling complex
Citation: BMC Pharmacology 2011 11(Suppl 1):O24 -
Cellular signaling mediated by nitrated cyclic nucleotide and regulated by hydrogen sulfide
Citation: BMC Pharmacology 2011 11(Suppl 1):O23 -
cGMP kinase I, cardiac hypertrophy and PDE inhibition
Citation: BMC Pharmacology 2011 11(Suppl 1):O19 -
Characterization of mice with a deletion of protein kinase G type I in cardiomyocytes and the effect on cardioprotection through either postconditioning or mitochondria-targeted S-nitrosothiol
Citation: BMC Pharmacology 2011 11(Suppl 1):O15 -
The crystal structures of PKG Iβ (92-227) with cGMP and cAMP reveal the molecular details of cyclic-nucleotide binding
Citation: BMC Pharmacology 2011 11(Suppl 1):O14 -
Genetic mapping of a modifier locus affecting hypertension in soluble guanylate cyclase α1 deficient mice
Citation: BMC Pharmacology 2011 11(Suppl 1):P14 -
Quantitation of cyclic nucleotides in mammalian cells and in human urine by high-performance liquid chromatography/mass spectrometry
Citation: BMC Pharmacology 2011 11(Suppl 1):P12 -
Protein kinase G I alpha activates an anti-remodeling signaling pathway in the heart via an interaction with the MAPKKK mixed lineage kinase 3
Citation: BMC Pharmacology 2011 11(Suppl 1):P9 -
Nitric oxide-independent stimulation of soluble guanylate cyclase attenuates pulmonary fibrosis
Citation: BMC Pharmacology 2011 11(Suppl 1):O9 -
Evidence for two catalytic centers and Mn2+ as physiological cofactor of soluble guanylyl cyclase
Citation: BMC Pharmacology 2011 11(Suppl 1):P7 -
Nitric oxide scavenging by red cell microparticles and cell free hemoglobin as a mechanism for hemolytic diseases and the red blood cell storage lesion
Citation: BMC Pharmacology 2011 11(Suppl 1):O7 -
Comparison of different vasodilators, endothelin antagonist, PDE5 inhibitior and sGC stimulators, in an animal model of secondary pulmonary hypertension: effects on “desaturation”
Citation: BMC Pharmacology 2011 11(Suppl 1):P5 -
Enhancing natriuretic peptide bioactivity prevents bleomycin-induced pulmonary fibrosis
Citation: BMC Pharmacology 2011 11(Suppl 1):P3 -
Additional stimulation of sGC on top of standard treatment with ARB`s may offer a new therapeutic approach for the treatment of diabetic nephropathy resistant to ARB treatment alone
Citation: BMC Pharmacology 2011 11(Suppl 1):P1 -
Dexamethasone restrains ongoing expression of interleukin-23p19 in peripheral blood-derived human macrophages
Since its recent discovery, interleukin-23 has been shown to be involved in the pathogenesis of autoimmune diseases favoring the development of a T cell subset referred to as T helper 17. Glucocorticoids are w...
Citation: BMC Pharmacology 2011 11:8 -
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
Breast cancers due to germline mutations or altered expression of the BRCA1 gene associate with an aggressive clinical course and frequently exhibit a "triple-negative" phenotype, i.e. lack of expression of the e...
Citation: BMC Pharmacology 2011 11:7 -
Differential effects of TRPV1 receptor ligands against nicotine-induced depression-like behaviors
The contributions of brain cannabinoid (CB) receptors, typically CB1 (CB type 1) receptors, to the behavioral effects of nicotine (NC) have been reported to involve brain transient receptor potential vanilloid...
Citation: BMC Pharmacology 2011 11:6 -
A web server for predicting inhibitors against bacterial target GlmU protein
The emergence of drug resistant tuberculosis poses a serious concern globally and researchers are in rigorous search for new drugs to fight against these dreadful bacteria. Recently, the bacterial GlmU protein...
Citation: BMC Pharmacology 2011 11:5 -
Synthesis of 86 species of 1,5-diaryl-3-oxo-1,4-pentadienes analogs of curcumin can yield a good lead in vivo
Curcumin is known to possess many anti-tumor properties such as inhibition of tumor growth and induction of apotosis. However, limited bioavailability of curcumin prevents its clinical application. A synthesiz...
Citation: BMC Pharmacology 2011 11:4 -
Altered 5-HT2C receptor agonist-induced responses and 5-HT2C receptor RNA editing in the amygdala of serotonin transporter knockout mice
The serotonin 5-HT2C receptor (5-HT2CR) is expressed in amygdala, a region involved in anxiety and fear responses and implicated in the pathogenesis of several psychiatric disorders such as acute anxiety and post...
Citation: BMC Pharmacology 2011 11:3 -
Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro
Rasagiline, a new drug developed to treat Parkinson's disease, is known to inhibit monoamine oxidase B. However, its metabolite R-(-)-aminoindan does not show this kind of activity. The present series of in vi...
Citation: BMC Pharmacology 2011 11:2 -
The boron-oxygen core of borinate esters is responsible for the store-operated calcium entry potentiation ability
Store-Operated Calcium Entry (SOCE) is the major Ca2+ ion entry pathway in lymphocytes and is responsible of a severe combined immunodeficiency (SCID) when deficient. It has recently been observed or highlighted ...
Citation: BMC Pharmacology 2011 11:1 -
Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study
Interferon (IFN) alpha conjugation to polyethylene glycol (PEG) results in a better pharmacokinetic profile and efficacy. The aim of this study was to compare the pharmacokinetic, pharmacodynamic and safety pr...
Citation: BMC Pharmacology 2010 10:15 -
Altered sodium channel function in dystrophin/utrophin-deficient cardiomyocytes
Citation: BMC Pharmacology 2010 10(Suppl 1):A25 -
A molecular switch between the outer and the inner vestibules of the voltage-gated Na+ channel
Citation: BMC Pharmacology 2010 10(Suppl 1):A23 -
Calmodulin kinase II regulates amphetamine-induced reverse transport in the dopamine transporter: implications for the importance of the dopamine transporter in Angelman syndrome
Citation: BMC Pharmacology 2010 10(Suppl 1):A19 -
The trafficking of GPR55 is regulated by the G protein-coupled receptor-associated sorting protein 1
Citation: BMC Pharmacology 2010 10(Suppl 1):A1